Institut De Recherches Internationales Servier IRIS
CompanyFrance
Institut De Recherches Internationales Servier IRIS develops 3 assets, the furthest in phase 3 (Dapagliflozin/Bisoprolol fumarate in heart failure). Mostly small molecule; based in France.
- 3
- Assets
- Furthest stage
- Phase 3
- 1
- Trial
- 3
- Signals
Pipeline
3Dapagliflozin/Bisoprolol fumarate
Combines SGLT2 inhibition and beta-1 adrenergic blockade to treat heart failure.
Phase 3, Small molecule, heart failure
Dapagliflozin/Bisoprolol fumarate/Eplerenone
Combines SGLT2 inhibition, beta-1 adrenergic blockade, and mineralocorticoid receptor antagonism to treat heart failure.
Phase 3, Small molecule, heart failure
Combines SGLT2 inhibition and mineralocorticoid receptor antagonism to treat heart failure.
Phase 3, Small molecule, heart failure
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials1
- Signals3
- Similar companies6